Home/Filings/4/0001415889-24-026867
4//SEC Filing

Tanimoto Sarina 4

Accession 0001415889-24-026867

CIK 0001671858other

Filed

Nov 13, 7:00 PM ET

Accepted

Nov 14, 4:30 PM ET

Size

14.2 KB

Accession

0001415889-24-026867

Insider Transaction Report

Form 4
Period: 2024-11-12
Tanimoto Sarina
CHIEF MEDICAL OFFICER10% Owner
Transactions
  • Sale

    Common Stock

    2024-11-12$16.76/sh45,045$754,9051,301,449 total(indirect: By Trust)
  • Sale

    Common Stock

    2024-11-12$17.64/sh4,955$87,4211,296,494 total(indirect: By Trust)
  • Sale

    Common Stock

    2024-11-12$16.76/sh45,124$756,2961,253,375 total(indirect: By Trust)
  • Sale

    Common Stock

    2024-11-12$17.64/sh4,876$86,0201,248,499 total(indirect: By Trust)
Holdings
  • Common Stock

    3,407,847
  • Common Stock

    (indirect: By Trust)
    1,397,447
  • Common Stock

    (indirect: By Spouse)
    4,315,313
Footnotes (8)
  • [F1]The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.
  • [F2]The weighted average sale price for the transaction report was $16.7589, and the range of prices were between $16.405 and $17.395. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • [F3]The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
  • [F4]The weighted average sale price for the transaction reported was $17.643, and the range of prices were between $17.42 and $17.85. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • [F5]The weighted average sale price for the transaction reported was $16.7604, and the range of prices were between $16.40 and $17.39. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • [F6]The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of the trust.
  • [F7]The weighted average sale price for the transaction reported was $17.6416, and the range of prices were between $17.42 and $17.83. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • [F8]The Reporting Person is trustee of the trust.

Issuer

ARS Pharmaceuticals, Inc.

CIK 0001671858

Entity typeother

Related Parties

1
  • filerCIK 0001951291

Filing Metadata

Form type
4
Filed
Nov 13, 7:00 PM ET
Accepted
Nov 14, 4:30 PM ET
Size
14.2 KB